Dostarlimab vs Sasanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline and partners
NCT04655976 · Phase 2/3 · active, not recruiting
Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.
Next expected readout: January 2027 · NCT06879717 (registry estimate)
Reported efficacy
Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)
Result source: NCT04655976
Sasanlimab
Developed by Pfizer
NCT04181788 · Phase 1/2 · completed
Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.
Reported efficacy
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)
Result source: NCT04181788
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dostarlimab | Sasanlimab |
|---|---|---|
| PFS, median | 4.4 vs 4.1vs DocetaxelNCT046559762 other results
| —Trial running · NCT06218069 |
| OS, median | 11.9 vs 11.3vs DocetaxelNCT046559763 other results
| 14.7bNCT025732591 other result
|
| ORR | 18.7% vs 14.5%vs DocetaxelNCT046559762 other results
| 16.4%bNCT025732593 other results
|
| Duration of response, median | 8.3 vs 8.8vs DocetaxelNCT046559762 other results
| —Trial running · NCT06218069 |
PFS, median
- Dostarlimab
- 4.4 vs 4.1vs DocetaxelNCT04655976
2 other results
- 4.2 vs 4.1 NCT04655976
- 4.4 NCT03308942
- Sasanlimab
- —Trial running · NCT06218069
OS, median
- Dostarlimab
- 11.9 vs 11.3vs DocetaxelNCT04655976
3 other results
- 11.8 vs 11.3 NCT04655976
- 11.9 NCT04655976
- 11.8 NCT04655976
- Sasanlimab
- 14.7bNCT02573259
1 other result
- 10.9 NCT02573259
ORR
- Dostarlimab
- 18.7% vs 14.5%vs DocetaxelNCT04655976
2 other results
- 18.3% vs 14.5% NCT04655976
- 9.1% NCT03308942
- Sasanlimab
- 16.4%bNCT02573259
3 other results
- 18.4% NCT02573259
- 19.4% NCT02573259
- 21.1% NCT02573259
Duration of response, median
- Dostarlimab
- 8.3 vs 8.8vs DocetaxelNCT04655976
2 other results
- 7.1 vs 8.8 NCT04655976
- 21.5 NCT03308942
- Sasanlimab
- —Trial running · NCT06218069
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Dostarlimab: 5 of 6 rows · Sasanlimab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dostarlimab Rows use multiple source trials | Sasanlimab |
|---|---|---|
| ORR responder rate · % of participants No placebo or comparator arm | 9.1% (n=11)a,b,c,d NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 16.4% (n=67)300 mg SCe,a,b,c,d NCT02573259 · Phase 1 · registry result, not featured evidence show 3 more doses19.4% (n=67)300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 18.4% (n=38)300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 21.1% (n=38)300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 11.9 monthse,f,b,c,d NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 1 more dose11.8 months NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 | 14.7 months300 mg SCe,f,b,c,d NCT02573259 · Phase 1 · registry result, not featured evidence show 1 more dose10.9 months300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence |
| Dropout rate | 25.6%Cobolimab + Dostarlimab + Docetaxeg NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results21.6%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | n/a: no completion milestone600 mg SC Q6Wh NCT04181788 · Phase 1/2 show 12 more resultsn/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 86.7%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.3%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 87.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.7%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 75%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 100%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Cobolimab + Dostarlimab + Docetaxeg NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results—Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 16.7%600 mg SC Q6Wh NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 3.8%600 mg SC Q6W NCT04181788 · Phase 1/2 0%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 2.4%300 mg SC Q4W NCT04181788 · Phase 1/2 —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 33.8%Cobolimab + Dostarlimab + Docetaxeg NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results42.7%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 58.3%Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 0%600 mg SC Q6Wh NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 16.3%600 mg SC Q6W NCT04181788 · Phase 1/2 25%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 39%300 mg SC Q4W NCT04181788 · Phase 1/2 20%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 26.5%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 34.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 42.9%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g anaemia 34.8% neutropenia 31.5% fatigue 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 2 more resultsanaemia 31.5% fatigue 29.8% diarrhoea 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 nausea 58.3% diarrhoea 50% fatigue 41.7% NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 600 mg SC Q6Wh pruritus 50% alanine aminotransferase increased 16.7% alopecia 16.7% NCT04181788 · Phase 1/2 show 12 more results600 mg SC Q6W anaemia 50% blood glucose increased 33.3% blood bilirubin increased 25% NCT04181788 · Phase 1/2 300 mg SC Q4W alanine aminotransferase increased 25% anaemia 25% aspartate aminotransferase increased 25% NCT04181788 · Phase 1/2 300 mg SC decreased appetite 46.7% nausea 40% dyspnoea 33.3% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 19.1% dyspnoea 14.7% decreased appetite 13.2% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 31.6% asthenia 15.8% back pain 15.8% NCT02573259 · Phase 1 · registry result, not featured evidence 10 mg/kg IV generalised oedema 57.1% constipation 42.9% aspartate aminotransferase increased 28.6% NCT02573259 · Phase 1 · registry result, not featured evidence 3 mg/kg IV generalised oedema 50% arthralgia 37.5% blood thyroid stimulating hormone increased 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 1 mg/kg IV constipation 50% decreased appetite 37.5% generalised oedema 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 0.5 mg/kg IV back pain 100% blood creatinine increased 100% constipation 100% NCT02573259 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 1 versus Phase 2.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 1 versus Phase 2/3.
- gPopulation comparability has not been reviewed for 2 of these studies.
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dostarlimab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Sasanlimab
show 9 more results
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Sasanlimab's landscape